Posts Tagged: MI Member Institutions

Triphase Accelerator announces new cancer collaboration with Sunnybrook Research Institute

TORONTO and SAN DIEGO (Feb. 26, 2015) — Triphase Accelerator Corporation has entered into an academic center collaboration with Sunnybrook Research Institute (SRI), the research arm of Sunnybrook Health Sciences Centre, a MaRS Innovation member institution. MaRS Innovation is also a Triphase investor. Under the agreement, SRI will assist in the development of Triphase’s novel, first-in-class, fully human bi-specific antibody TRPH 011 and evaluate the role of bifunctional targeting of VEGFR-2 and TIE 2 receptors in cancer. TRPH 011 binds and neutralizes VEGFR-2/KDR ... Read more

MaRS Innovation’s top 10 portfolio stories for 2014

MaRS Innovation enjoyed an exceptional year in 2014. Our team continues to collaborate with researchers within our membership to help bridge the commercialization gap between their world-leading research and creating successful start-up companies or licenses. Here are our picks for the top 10 news stories from MaRS Innovation's portfolio. 1. Triphase Accelerator Corporation, in which MaRS Innovation is an investor, started the year with a bang by signing a collaboration and option agreement with Celgene Corporation. In October, Triphase initiated a Phase I clinical study ... Read more

UTEST gets a mention in TechVibes piece on Canada’s growing start-up scene

TechVibes gave UTEST, an incubator program jointly run by MaRS Innovation and the University of Toronto, a mention in Laura Leslie's "Canada’s Startup Communities Shining Brighter Than the California Sun," published November 24, 2014, which explores the ecosystem-wide supports in place to encourage entrepreneurship in Canada. Leslie writes: Silicon Valley may be the first place that comes to mind when you think of tech startups, but when considering resources, financial support, and a welcoming atmosphere, Canada has been steadily putting itself on the map. ... Read more

MaRS Innovation Industry Access Program (MI-IAP) accepting applications until April 10

Researchers working in orphan indications, drug delivery devices, big data and other key areas invited to submit a brief Statement of Interest The MaRS Innovation Industry Access Program (MI-IAP) is a simple, formalized process for marketing early-stage technologies to MI's industry partners: Baxter, LifeLabs (formerly CML Healthcare), GSK, Johnson & Johnson, Pfizer and Merck. The program's goal is to secure funding for researchers within MI's membership through these collaborative, strategic R&D partnership programs. First run in November 2013, the MI-IAP allows researchers to easily ... Read more

Bioprinter covered on CTV’s Canada AM

The Bioprinter project, a three-way initiative from MaRS Innovation, the University of Toronto and Sunnybrook Health Sciences Centre, was featured on Canada AM on January 29 during a segment with Dr. Marla Shapiro, the program's Health and Medical Expert. The Bioprinter, whose commercial applications are being developed by MI's Fanny Sie, is a 3D printer than can print on organic material, including skin. Click here to watch the full segment on CTV's Canada AM.  Shapiro visited Dr. Marc Jeschke and his team in his lab at Sunnybrook to ... Read more

MaRS Innovation and Pfizer fund Bio-Manufacturing Technology

Technology developed by Dr. Stuart Berger at UHN is first project funded through partnership TORONTO, Dec. 11, 2013 - MaRS Innovation, a Centre of Excellence for Commercialization and Research, has announced the first project funded through the Pfizer Inc. and MaRS Innovation strategic partnership. Dr. Stuart Berger, senior scientist at University Health Network, has developed a potential innovation for the bio-manufacturing sector, which is a rapid-growth area. This announcement was covered by BetaKit. His technology generates cell lines with improved protein production and survival properties, important in the ... Read more

MaRS Innovation launches streamlined funding program

Applications invited for MI’s Industry Access Program, which matches early-stage, high-potential technologies to partners and funding MaRS Innovation (MI) has launched a unique funding program to match researchers with industry partners while advancing early stage technologies: the MaRS Innovation Industry Access Program (MI-IAP). This program provides a simple mechanism to connect researchers with MI’s industry partners. The process and application form are intentionally brief to save researchers time and allow MI's partners to review a wide range of remarkable technologies within the Toronto academic ... Read more

Dr. Raphael Hofstein’s MRI blog post: How Team Ontario’s biotechnology takes on the world

Dr. Raphael (Rafi) Hofstein is president and CEO of MaRS Innovation (MI) – the commercialization agent for an exceptional research discovery pipeline stemming from 16 leading Ontario academic institutions. As a single entry point to annual member research and development activity of $1B, MI provides a gateway for investors and licensees who wish to access Ontario’s technology assets. During the 2012 BIO convention in Boston, Dr. Hofstein blogged about how CQDM of Montreal and MaRS Innovation of Toronto had teamed up to ... Read more

MaRS Innovation announces new strategic partnership with Pfizer

TORONTO, April 22, 2013 — MaRS Innovation, a Centre of Excellence for Commercialization and Research, today announced the formation of a strategic partnership with Pfizer Inc. to advance early-stage technologies related to human health in therapeutics and diagnostics. Through this collaboration, MaRS Innovation and Pfizer will jointly identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals. “There’s growing consensus that transferring technologies from the university lab ... Read more

Stem Cell Therapeutics licenses UHN’s Clinical Cancer Stem Cell Program

Stem Cell Therapeutics Corp. (TSX-V: SSS), a biopharmaceutical company developing cancer stem cell-related technologies, has signed a definitive license agreement with University Health Network (UHN), Toronto, Canada. The agreement, developed in collaboration with MaRS Innovation, provides Stem Cell Therapeutics (SCT) with exclusive worldwide rights to an innovative clinical cancer stem cell program. This announcement builds upon the existing stem cell program agreement between MI, Stem Cell Therapeutics and UHN, which was announced in November 2012. The initial consideration of $1.6 million for the UHN ... Read more
Page 1 of 3123